Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched ...

What is RSI?: Recursive self-improvement refers to AI systems enhancing their own capabilities, potentially accelerating innovation beyond human pace. Recent breakthroughs: Firms like OpenAI and ...

Recursive self-improvement is emerging, but humans are still in the loop ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

For example, Nvidia owns stakes in six smaller companies. I think Recursion Pharmaceuticals (RXRX 3.62%) is arguably the most intriguing of the group. Recursion looks like a big dud so far. The ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027. Recursion ...

Abstract: This paper proposes a passivity-based Recursive Newton-Euler algorithm, abbreviated pRNE. The proposed pRNE algorithm solves the inverse dynamics under a ...

Recursion has rapidly established itself as a leader in the field of AI-enabled biotechnology. The company's BioHive-2 supercomputer, powered by Nvidia AI chips, is one of the world's most powerful ...

Abstract: In recent years, the spotlight of research in the adaptive learning era has turned toward distributed adaptive filtering algorithms for sparse systems over ...

Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...